Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
CONCLUSIONS: Although imiquimod induced a higher regression to CIN1 or less and significant increases in CD4/CD8 T cells infiltrating the cervix, it did not meet its prespecified statistical outcome for efficacy. A higher regression rate than expected was observed in the surveillance arm of this prospective trial. Future clinical trials with imiquimod targeting CIN3 patients are warranted.PMID:38592381 | DOI:10.1158/1078-0432.CCR-23-3639 (Source: Cancer Control)
Source: Cancer Control - April 9, 2024 Category: Cancer & Oncology Authors: Sangini S Sheth Ji Eun Oh Stefania Bellone Eric R Siegel Michelle Greenman Levent Mutlu Blair McNamara Shefali Pathy Mitchell Clark Masoud Azodi Gary Altwerger Vaagn Andikyan Gloria Huang Elena Ratner Daniel J Kim Akiko Iwasaki Angelique W Levi Natalia Bu Source Type: research
Epidemiology of human papillomavirus infection in women from Xiamen, China, 2013 to 2023
CONCLUSION: The study provided the largest scale information on the recent epidemiological characteristics of HPV infection in Xiamen, and even in Fujian Province, China, which would support making the prevention and control strategies for cervical cancer in the region.PMID:38590815 | PMC:PMC11000419 | DOI:10.3389/fpubh.2024.1332696 (Source: Cancer Control)
Source: Cancer Control - April 9, 2024 Category: Cancer & Oncology Authors: Xingmei Yao Qing Li Yu Chen Zhuowen Du Yanru Huang Yixi Zhou Jian Zhang Wenbo Wang Lutan Zhang Jieqiong Xie Chao Xu Yunsheng Ge Yulin Zhou Source Type: research
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
CONCLUSIONS: Although imiquimod induced a higher regression to CIN1 or less and significant increases in CD4/CD8 T cells infiltrating the cervix, it did not meet its prespecified statistical outcome for efficacy. A higher regression rate than expected was observed in the surveillance arm of this prospective trial. Future clinical trials with imiquimod targeting CIN3 patients are warranted.PMID:38592381 | DOI:10.1158/1078-0432.CCR-23-3639 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 9, 2024 Category: Cancer & Oncology Authors: Sangini S Sheth Ji Eun Oh Stefania Bellone Eric R Siegel Michelle Greenman Levent Mutlu Blair McNamara Shefali Pathy Mitchell Clark Masoud Azodi Gary Altwerger Vaagn Andikyan Gloria Huang Elena Ratner Daniel J Kim Akiko Iwasaki Angelique W Levi Natalia Bu Source Type: research
Enhancing Immune Response in Non-Small-Cell Lung Cancer Patients: Impact of the 13-Valent Pneumococcal Conjugate Vaccine
Conclusions: We hope that our research will contribute to increasing patients' and physicians' awareness of the importance of including PCV13 vaccinations in the standard of oncological care, which will extend the survival time of patients and improve their quality of life.PMID:38592328 | PMC:PMC10933946 | DOI:10.3390/jcm13051520 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Jolanta Smok-Kalwat Paulina Mertowska Izabela Korona-G łowniak Sebastian Mertowski Paulina Nied źwiedzka-Rystwej Dominika B ębnowska Krzysztof Gosik Andrzej Stepulak Stanis ław Góźdź Jacek Roli ński Zofia G órecka Jan Siwiec Ewelina Grywalska Source Type: research
Significantly Elevated CA 19-9 after COVID-19 Vaccination and Literature Review of Non-Cancerous Cases with CA 19-9 & gt; 1000 U/mL
CONCLUSIONS: Conducting differential diagnosis, it should not be forgotten that most international guidelines recommend the use of CA 19-9 only in conjunction with pathology of pancreas in radiological imaging; however, even such a combination can point the diagnostic pathway in the wrong direction. A highly elevated CA 19-9 level, typically associated with PDAC, may be the result of benign disease including AIP related to COVID-19 vaccination.PMID:38592088 | PMC:PMC10932348 | DOI:10.3390/jcm13051263 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Jakub Ciesielka Krzysztof Jakim ów Natalia Tekiela Laura Peisert Anna Kwa śniewska Dariusz Kata Jerzy Chudek Source Type: research
Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
AbstractDespite recent advancements in the diagnosis and treatment of breast cancer (BC), patient outcomes in terms of survival, recurrence, and disease progression remain suboptimal. A significant factor contributing to these challenges is the cellular heterogeneity within BC, particularly the presence of breast cancer stem cells (BCSCs). These cells are thought to serve as the clonogenic nexus for new tumor growth, owing to their hierarchical organization within the tumor. This descriptive review focuses on the evolving strategies to target BCSCs, which have become a pivotal aspect of therapeutic development. We explore ...
Source: Medical Oncology - April 9, 2024 Category: Cancer & Oncology Source Type: research
The deadlock on HPV vaccination in Japan is almost broken!
Primary and secondary prevention have the potential to eliminate cervical cancer. On 17 November 2020, the World Health Organization (WHO) launched a global strategy for the accelerated elimination of cervical cancer [1]. By the end of the century, the WHO wants to reduce the cervical cancer incidence below 4 per 100,000 women. The strategy is based on three pillars: (1) vaccination: 90% of girls fully vaccinated with the HPV vaccine by the age of 15; (2) screening: 70% of women screened using a high-performance test by the age of 35, and again by the age of 45; (3) treatment: 90% of women with pre-cancer treated and 90% o...
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - April 9, 2024 Category: OBGYN Authors: Wiebren A.A. Tjalma, Ryo Konno, Jaques van Heerden Source Type: research
Analysis of SARS-CoV-2 omicron mutations that emerged during long-term replication in a lung cancer xenograft mouse model
AbstractSARS-CoV-2 Omicron has the largest number of mutations among all the known SARS-CoV-2 variants. The presence of these mutations might explain why Omicron is more infectious and vaccines have lower efficacy to Omicron than other variants, despite lower virulence of Omicron. We recently established a long-term in vivo replication model by infecting Calu-3 xenograft tumors in immunodeficient mice with parental SARS-CoV-2 and found that various mutations occurred majorly in the spike protein during extended replication. To investigate whether there are differences in the spectrum and frequency of mutations between pare...
Source: Virus Genes - April 8, 2024 Category: Genetics & Stem Cells Source Type: research
Structured Literature Review to Identify Human Papillomavirus ’s Natural History Parameters for Dynamic Population Models of Vaccine Impacts
This study aimed to identify and synthesize data needed to parametrize DTMs on the natural history of HPV infection and related diseases. Parameters describing data of interest were grouped by their anatomical location (genital warts, recurrent respiratory papillomatosis, and cervical, anal, vaginal, vulvar, head and neck, and penile cancers), and natural history (progression, regression, death, cure, recurrence, detection), and were identified through a systematic literature review (SLR) and complementary targeted literature reviews (TLRs). The extracted data were then synthesized by pooling parameter values across public...
Source: Infectious Diseases and Therapy - April 8, 2024 Category: Infectious Diseases Source Type: research
Digital Health Interventions for Cancer Prevention Among Racial and Ethnic Minority Groups in the United States: A Scoping Review
ConclusionsWe identified several notable gaps regarding digital health for cancer prevention among racial/ethnic minority groups. Addressing these gaps may help guide continued innovation in the use of digital health for cancer prevention among racial/ethnic minority groups. (Source: Journal of Racial and Ethnic Health Disparities)
Source: Journal of Racial and Ethnic Health Disparities - April 8, 2024 Category: International Medicine & Public Health Source Type: research
Structured Literature Review to Identify Human Papillomavirus ’s Natural History Parameters for Dynamic Population Models of Vaccine Impacts
This study aimed to identify and synthesize data needed to parametrize DTMs on the natural history of HPV infection and related diseases. Parameters describing data of interest were grouped by their anatomical location (genital warts, recurrent respiratory papillomatosis, and cervical, anal, vaginal, vulvar, head and neck, and penile cancers), and natural history (progression, regression, death, cure, recurrence, detection), and were identified through a systematic literature review (SLR) and complementary targeted literature reviews (TLRs). The extracted data were then synthesized by pooling parameter values across public...
Source: Infectious Diseases and Therapy - April 8, 2024 Category: Infectious Diseases Source Type: research
Review: N1-methyl-pseudouridine (m1 Ψ): Friend or foe of cancer?
Int J Biol Macromol. 2024 Apr 5:131427. doi: 10.1016/j.ijbiomac.2024.131427. Online ahead of print.ABSTRACTDue to the health emergency created by SARS-CoV-2, the virus that causes the COVID-19 disease, the rapid implementation of a new vaccine technology was necessary. mRNA vaccines, being one of the cutting-edge new technologies, attracted significant interest and offered a lot of hope. The potential of these vaccines in preventing admission to hospitals and serious illness in people with comorbidities has recently been called into question due to the vaccines' rapidly waning immunity. Mounting evidence indicates that the...
Source: International Journal of Biological Macromolecules - April 7, 2024 Category: Biochemistry Authors: Alberto Rubio-Casillas David Cowley Mikolaj Raszek Vladimir N Uversky Elrashdy M Redwan Source Type: research
Review: N1-methyl-pseudouridine (m1 Ψ): Friend or foe of cancer?
Int J Biol Macromol. 2024 Apr 5:131427. doi: 10.1016/j.ijbiomac.2024.131427. Online ahead of print.ABSTRACTDue to the health emergency created by SARS-CoV-2, the virus that causes the COVID-19 disease, the rapid implementation of a new vaccine technology was necessary. mRNA vaccines, being one of the cutting-edge new technologies, attracted significant interest and offered a lot of hope. The potential of these vaccines in preventing admission to hospitals and serious illness in people with comorbidities has recently been called into question due to the vaccines' rapidly waning immunity. Mounting evidence indicates that the...
Source: International Journal of Biological Macromolecules - April 7, 2024 Category: Biochemistry Authors: Alberto Rubio-Casillas David Cowley Mikolaj Raszek Vladimir N Uversky Elrashdy M Redwan Source Type: research
Oligonucleotide based nanogels for cancer therapeutics
Int J Biol Macromol. 2024 Apr 4:131401. doi: 10.1016/j.ijbiomac.2024.131401. Online ahead of print.ABSTRACTOligonucleotide-based nanogels, as nascent biomaterials, possess several unique functional, structural, and physicochemical features with excellent drug-loading capacity and high potential for cancer gene therapy. Ongoing studies utilizing oligonucleotide-based nanogels hold great promise, as these cutting-edge nanoplatforms can be elegantly developed with predesigned oligonucleotide sequences and complementary strands which are self-assembled or chemically crosslinked leading to the development of nanogels with predi...
Source: International Journal of Biological Macromolecules - April 6, 2024 Category: Biochemistry Authors: Hooman Hatami Niloufar Rahiman Marzieh Mohammadi Source Type: research
Role of immunotherapies and stem cell therapy in the management of liver cancer: A comprehensive review
Int Immunopharmacol. 2024 Apr 5;132:112011. doi: 10.1016/j.intimp.2024.112011. Online ahead of print.ABSTRACTLiver cancer (LC) is the sixth most common disease and the third most common cause of cancer-related mortality. The WHO predicts that more than 1 million deaths will occur from LC by 2030. Hepatocellular carcinoma (HCC) is a common form of primary LC. Today, the management of LC involves multiple disciplines, and multimodal therapy is typically selected on an individual basis, considering the intricate interactions between the patient's overall health, the stage of the tumor, and the degree of underlying liver disea...
Source: International Immunopharmacology - April 6, 2024 Category: Allergy & Immunology Authors: Fares E M Ali Islam M Ibrahim Hanan S Althagafy Emad H M Hassanein Source Type: research
